Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2010

View Archived Issues

4-PBA and curcumin enhance protein expression of mutant ATP7B / News in Context

Genzyme reports 2-year data from phase II Gaucher's disease trial

Bristol-Myers Squibb reports results from fourth quarter 2009, ended December 31

Shionogi files additional application in Japan for pediatric use of Rapiacta

Oxigene presents update on development of Zybrestat

3SBio submits application in China for phase I clinical trial of NuPIAO

Debiopharm's Clinical Trial Application for Debio-0932 approved in France

Helix reports preliminary results from phase II study of topical interferon alpha-2b

ADX-71943 demonstrates analgesic effects in preclinical pain models

Repros submits response to FDA regarding Androxal in hypogonadism

LJ-001, a broad-spectrum antiviral targeting the viral lipid membrane

Solvay claims novel adenosine A1 receptor antagonists

Amakem starts operations to discover and develop novel kinase inhibitors

Bristol-Myers Squibb claims MAP kinase inhibitors for inflammatory disorders

Millennium Pharmaceuticals patents novel proteasome inhibitors

Older vaccines provide protection against 2009 pandemic H1N1 influenza

Genentech identifies new Janus kinase inhibitors

Roche claims monoamine reuptake inhibitors for the treatment of affective disorders

HDAC inhibitor SAHA restores activity of mutant CFTR in vitro

Fingolimod shows clinical benefit in two phase III trials in relapsing-remitting MS

AVI BioPharma receives grants for Duchenne muscular dystrophy drug development

Toyama initiates U.S. phase II trial for its anti-influenza drug candidate, T-705

Abbott acquires Solvay Pharmaceuticals for EUR 4.5 billion

AstraZeneca and Rigel sign license agreement for fostamatinib disodium in RA

Pharmaxis completes phase I clinical trial of PXS-25 in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...